| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $20,798 | 2 | 13 |
Sells | $3,144,594 | 14 | 87 |
| Easom Eric | Chief Executive Officer | 1 | $10,665 | 0 | $0 | $10,665 |
| FitzPatrick Margaret M | director | 1 | $10,133 | 0 | $0 | $10,133 |
| Williams Sarah Joanne | Principal Accounting Officer | 0 | $0 | 1 | $347 | $-347 |
| Prior Stephen David | Chief Strategy Officer | 0 | $0 | 3 | $7,379 | $-7,379 |
| Day Lucy | Chief Financial Officer | 0 | $0 | 2 | $8,883 | $-8,883 |
| Chanda Sanjay | Chief Development Officer | 0 | $0 | 2 | $9,332 | $-9,332 |
| Eizen Joshua M | See Remarks | 0 | $0 | 3 | $28,176 | $-28,176 |
| Leonard Braden Michael | 10 percent owner | 0 | $0 | 3 | $3.09M | $-3.09M |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Over the last 12 months, insiders at AN2 Therapeutics, Inc. have bought $20,798 and sold $3.14M worth of AN2 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at AN2 Therapeutics, Inc. have bought $13.67M and sold $4.68M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Easom Eric (Chief Executive Officer) — $10,665. FitzPatrick Margaret M (director) — $10,133.
The last purchase of 10,000 shares for transaction amount of $10,665 was made by Easom Eric (Chief Executive Officer) on 2025‑06‑02.
| 2026-03-03 | Sale | Williams Sarah Joanne | Principal Accounting Officer | 327 0.0012% | $1.06 | $347 | +337.35% | |
| 2026-01-06 | Sale | Eizen Joshua M | See Remarks | 6,931 0.0239% | $1.01 | $7,014 | +5.61% | |
| 2026-01-06 | Sale | Chanda Sanjay | Chief Development Officer | 5,956 0.0206% | $1.01 | $6,027 | +5.61% | |
| 2026-01-06 | Sale | Day Lucy | Chief Financial Officer | 5,512 0.019% | $1.01 | $5,578 | +5.61% | |
| 2026-01-06 | Sale | Prior Stephen David | Chief Strategy Officer | 2,858 0.0099% | $1.01 | $2,892 | +5.61% | |
| 2026-01-05 | Sale | Eizen Joshua M | See Remarks | 17,923 0.0612% | $1.00 | $17,948 | +5.61% | |
| 2026-01-05 | Sale | Chanda Sanjay | Chief Development Officer | 3,295 0.0113% | $1.00 | $3,305 | +5.61% | |
| 2026-01-05 | Sale | Day Lucy | Chief Financial Officer | 3,295 0.0113% | $1.00 | $3,305 | +5.61% | |
| 2026-01-05 | Sale | Prior Stephen David | Chief Strategy Officer | 3,604 0.0123% | $1.00 | $3,615 | +5.61% | |
| 2025-11-04 | Sale | Eizen Joshua M | See Remarks | 2,819 0.0096% | $1.14 | $3,214 | -1.75% | |
| 2025-11-04 | Sale | Prior Stephen David | Chief Strategy Officer | 765 0.0026% | $1.14 | $872 | -1.75% | |
| 2025-06-02 | Easom Eric | Chief Executive Officer | 10,000 0.0333% | $1.07 | $10,665 | +6.60% | ||
| 2025-05-30 | Sale | Leonard Braden Michael | 10 percent owner | 432,000 1.3646% | $1.01 | $436,477 | +6.60% | |
| 2025-05-28 | Sale | Leonard Braden Michael | 10 percent owner | 2.1M 7.0198% | $1.16 | $2.44M | -1.74% | |
| 2025-05-28 | Sale | Leonard Braden Michael | 10 percent owner | 200,000 0.6282% | $1.09 | $218,000 | -1.74% | |
| 2025-05-28 | FitzPatrick Margaret M | director | 8,610 0.0292% | $1.18 | $10,133 | -1.74% | ||
| 2025-01-03 | Sale | Eizen Joshua M | See Remarks | 9,663 0.0304% | $1.34 | $12,958 | -17.61% | |
| 2025-01-03 | Sale | Prior Stephen David | Chief Strategy Officer | 2,029 0.0064% | $1.34 | $2,721 | -17.61% | |
| 2025-01-03 | Sale | Day Lucy | Chief Financial Officer | 2,957 0.0093% | $1.34 | $3,965 | -17.61% | |
| 2025-01-03 | Sale | Chanda Sanjay | Chief Development Officer | 2,957 0.0093% | $1.34 | $3,965 | -17.61% |
| Leonard Braden Michael | 10 percent owner | 3217432 11.7416% | $15.89M | 1 | 3 | +7.62% |
| Easom Eric | Chief Executive Officer | 256380 0.9356% | $1.27M | 3 | 17 | +21% |
| Eizen Joshua M | See Remarks | 152499 0.5565% | $753,345.06 | 0 | 4 | |
| Chanda Sanjay | Chief Development Officer | 75823 0.2767% | $374,565.62 | 0 | 3 | |
| Day Lucy | Chief Financial Officer | 75363 0.275% | $372,293.22 | 0 | 3 | |
| Williams Sarah Joanne | Principal Accounting Officer | 66848 0.244% | $330,229.12 | 0 | 1 | |
| Prior Stephen David | Chief Strategy Officer | 59086 0.2156% | $291,884.84 | 0 | 4 | |
| FitzPatrick Margaret M | director | 8610 0.0314% | $42,533.40 | 1 | 0 | |
| Shah Rajeev M. | 3773417 13.7706% | $18.64M | 5 | 0 | +11.29% | |
| Adjuvant Global Health Technology Fund DE, L.P. | 2210735 8.0678% | $10.92M | 1 | 0 | <0.0001% | |
| Readnour Robin Shane | director | 652573 2.3815% | $3.22M | 8 | 2 | <0.0001% |
| Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 377542 1.3778% | $1.87M | 1 | 10 | <0.0001% |
| Aziz Kabeer | director | 377542 1.3778% | $1.87M | 1 | 10 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 300853 1.0979% | $1.49M | 9 | 1 | +12.48% |
| Zakrzewski Joseph S | director | 125199 0.4569% | $618,483.06 | 3 | 1 | +7.58% |
| Krause Kevin Michael | Chief Strategy Officer | 1914 0.007% | $9,455.16 | 0 | 2 |
$9,405,928 | 107 | 12.61% | $117.96M | |
$66,137,559 | 49 | 6.29% | $140.74M | |
$18,994,888 | 46 | 88.59% | $127.16M | |
$48,218,096 | 42 | 0.89% | $140.57M | |
$140,595,157 | 34 | 17.93% | $105.43M | |
$7,147,964 | 34 | 24.77% | $136.68M | |
$109,415,500 | 33 | 18.13% | $139.26M | |
$36,180,184 | 32 | 41.36% | $115.46M | |
AN2 Therapeutics, Inc. (ANTX) | $38,601,028 | 29 | 1.18% | $135.37M |
$295,092,700 | 21 | -0.27% | $136.03M | |
$111,692,551 | 18 | 13.51% | $142.01M | |
$3,556,951 | 18 | 9.64% | $101.17M | |
$178,593,887 | 15 | -14.86% | $120.79M | |
$156,530,514 | 13 | 45.71% | $107.37M | |
$9,999,920 | 10 | -40.03% | $120.54M | |
$13,919,584 | 9 | -30.43% | $144.79M | |
$2,762,881 | 8 | -10.76% | $142.01M | |
$5,524,590 | 7 | 7.40% | $140.29M | |
$68,692,148 | 6 | -39.10% | $102.12M |
| Increased Positions | 15 | +41.67% | 924,459 | +12.23% |
| Decreased Positions | 11 | -30.56% | 159,431 | -2.11% |
| New Positions | 6 | New | 669,045 | New |
| Sold Out Positions | 3 | Sold Out | 36,740 | Sold Out |
| Total Postitions | 40 | +11.11% | 8M | +10.12% |
| Almitas Capital Llc | $1,585.00 | 5.29% | 1.43M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $1,199.00 | 4% | 1.08M | +44,123 | +4.26% | 2025-09-30 |
| Peapod Lane Capital Llc | $654.00 | 2.18% | 589,216 | +6,446 | +1.11% | 2025-09-30 |
| Stonepine Capital Management, Llc | $626.00 | 2.09% | 563,913 | +19,419 | +3.57% | 2025-09-30 |
| Bank Of Nova Scotia | $510.00 | 1.7% | 459,194 | 0 | 0% | 2025-09-30 |
| Landscape Capital Management, L.L.C. | $507.00 | 1.69% | 456,463 | -38,933 | -7.86% | 2025-09-30 |
| Bank Of Montreal /Can/ | $469.00 | 1.56% | 422,077 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $428.00 | 1.43% | 385,597 | -13,257 | -3.32% | 2025-09-30 |
| Bank Of America Corp /De/ | $428.00 | 1.43% | 385,310 | -201 | -0.05% | 2025-09-30 |
| Blackrock, Inc. | $356.00 | 1.19% | 320,911 | +1,616 | +0.51% | 2025-09-30 |